Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count
Cancers · 24.10.2024 · 16 (21) · 3583
DOI: 10.3390/cancers16213583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.10.2024. Verfasst von Zitha Redempta Isingizwe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, University of Arizona Lauder Alberts Gift.
Abstract (Originalsprache)
Background
Patients with ovarian cancer have high platelet counts, which correlate with disease burden, incidence, and lethality of blood clots (thrombosis). We hypothesized that elevated aggregation is associated with both increased platelet number and altered behavior of platelets in patients with ovarian cancer.
Methods
Healthy controls and patients with suspected or diagnosed ovarian cancer were evaluated for complete blood counts. To evaluate the effects of platelet count versus platelet behavior, equal platelet-rich plasma (PRP) volumes versus equal platelet numbers were used in platelet aggregation assays. Arachidonic acid, adenosine diphosphate, and collagen platelet agonists were used to induce aggregation. Volunteers were grouped into healthy controls (23), benign/borderline cases (7), and cancer cases (25 ovarian, 1 colorectal, and 2 endometrial).
Results
The rate and amount of platelet aggregation were higher in patients compared to healthy controls regardless of whether the same platelet number or PRP volume was used. Compared to healthy controls, patients with untreated ovarian cancer exhibited high levels of platelet activation markers, P-selectin (27.06 vs. 31.06 ng/mL, p = 0.03), and beta-thromboglobulin (3.073 vs. 4.091 µg/mL, p = 0.02) in their plasma. The significance of the elevation and its correlations with platelet number or PRP volume varied depending on the agonist. Platelet (305.88 vs. 134.12, p < 0.0001) and white blood cell (8.459 vs. 5.395, p < 0.01) counts (×109/L) were elevated pre-chemotherapy and decreased post-chemotherapy, respectively.
Conclusions
Elevated platelet aggregation is caused by both altered platelet number and behavior in patients with ovarian cancer. These results support the study of antiplatelet agents for thrombosis prevention in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
ORCID-Profile: Zitha Redempta Isingizwe, Doris Mangiaracina Benbrook
Förderung
- NCI NIH HHS
- NIH HHS
- University of Arizona Lauder Alberts Gift
- National Cancer Institute Cancer Center
Zitieren
APA
Isingizwe, Z. R., Meelheim, B. A., & Benbrook, D. M. (2024). Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count. Cancers, 16(21), 3583. https://doi.org/10.3390/cancers16213583
Vancouver
Isingizwe ZR, Meelheim BA, Benbrook DM. Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count. Cancers. 2024;16(21):3583. doi:10.3390/cancers16213583
BibTeX
@article{Isingizwe2024,
author = {Isingizwe, Zitha Redempta and Meelheim, Brooke A and Benbrook, Doris Mangiaracina},
title = {Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count},
journal = {Cancers},
year = {2024},
volume = {16},
number = {21},
pages = {3583},
doi = {10.3390/cancers16213583}
}
EUVIMED